Silver Book

Silver Book Fact

Improvements in QoL from TAVR in SAS patients

Symptomatic aortic stenosis (SAS) patients who underwent transcatheter aortic valve replacement (TAVR) experienced quality of life (QoL) improvements from 5.3 at baseline (10 point scale with 10=best imaginable health state) to 6.7 at one year, and 7.4 at four years post procedure.

Kovac J, Schuler G, Gerckens U, Muller R, et al. Four-Year Experience with CoreValve Transcatheter Heart Valve. EuroInterven. 2016; 12(8): 1039-46. https://pubmed.ncbi.nlm.nih.gov/27159659/

Reference

Title
Four-Year Experience with CoreValve Transcatheter Heart Valve
Publication
EuroInterven
Publication Date
2016
Authors
Kovac J, Schuler G, Gerckens U, Muller R, et al.
Volume & Issue
Volume 12, Issue 8
Pages
1039-46
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Publications

Aortic Stenosis Fact Sheet

 https://www.silverbook.org/wp-content/uploads/2017/10/AS-FS-cover.png Thumbnail

Related Facts

  • Undertreatment of patients with sSAS
    AS is often undertreated — one study found that 56% of severe symptomatic aortic stenosis (sSAS) patients referred to a cardiothoracic surgeon were not operated on.  
  • TAVR v. SAVR in Intermediate-Risk SAS Patients
    At 1-year, severe aortic stenosis (SAS) patients with intermediate surgical mortality risk who underwent transcatheter aortic valve replacement (TAVR), had all-cause mortality rates of 7.4% (compared to 13% for surgical…  
  • Survival Rates of SAS Patients with and without SAVR
    Patients with severe aortic stenosis (SAS) ages 80+ who underwent surgical aortic valve replacement (SAVR) have 1-year, 2-year, and 5-year survival rates of 87%, 78%, and 68% respectively — compared with…  
  • Life expectancy and quality of life gains from AVR
    A study of 4,617 patients who underwent aortic valve replacement (AVR) over a period of 20 years found significant gains in life expectancy and quality of life — 43,166 net life-years…  
  • Cost-effectiveness of SAVR
    The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).